Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing
Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing
Nektar Therapeutics收到信函，稱其已恢復遵守繼續在納斯達克資本市場上市的最低出價要求——備案
To regain compliance with the Minimum Bid Price Requirement, the Company's common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business days. This requirement was met on April 16, 2024.
To regain compliance with the Minimum Bid Price Requirement, the Company's common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business days. This requirement was met on April 16, 2024.
爲了重新遵守最低出價要求，公司普通股必須至少連續10個工作日維持每股1.00美元或以上的收盤價。該要求已於 2024 年 4 月 16 日得到滿足。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！